BACKGROUND:Secretory phospholipase A(2) (sPLA(2)) may contribute to atherogenesis. To date, few prospective studies have examined the utility of sPLA(2) for risk stratification in coronary artery disease (CAD). METHODS: We measured plasma sPLA(2) activity at baseline in 3708 subjects in the PEACE randomized trial oftrandolapril vs placebo in stable CAD. Median follow-up was 4.8 years. We used Cox regression to adjust for demographics, clinical risk factors, apolipoprotein B, apolipoprotein A1, and medications. RESULTS: After multivariable adjustment, sPLA(2) was associated with an increased risk of cardiovascular death, myocardial infarction, or stroke (adjusted hazard ratio Q4:Q1 1.55, 95% CI 1.13-2.14) and cardiovascular death or heart failure (1.91, 1.20-3.03). In further multivariable assessment, increased activity levels of sPLA(2) were associated with the risk of cardiovascular death, myocardial infarction, or stroke (adjusted hazard ratio 1.47, 95% CI 1.06-2.04), independent of lipoprotein-associated phospholipase A(2) mass and C-reactive protein, and modestly improved the area under the curve (AUC) beyond established clinical risk factors (AUC 0.668-0.675, P = 0.01). sPLA(2), N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T all were independently associated with cardiovascular death or heart failure, and each improved risk discrimination (P = 0.02, P < 0.001, P < 0.001, respectively). CONCLUSIONS:sPLA(2) activity provides independent prognostic information beyond established risk markers in patients with stable CAD. These data are encouraging for studies designed to evaluate the role of sPLA(2) as a therapeutic target.
RCT Entities:
BACKGROUND:Secretory phospholipase A(2) (sPLA(2)) may contribute to atherogenesis. To date, few prospective studies have examined the utility of sPLA(2) for risk stratification in coronary artery disease (CAD). METHODS: We measured plasma sPLA(2) activity at baseline in 3708 subjects in the PEACE randomized trial of trandolapril vs placebo in stable CAD. Median follow-up was 4.8 years. We used Cox regression to adjust for demographics, clinical risk factors, apolipoprotein B, apolipoprotein A1, and medications. RESULTS: After multivariable adjustment, sPLA(2) was associated with an increased risk of cardiovascular death, myocardial infarction, or stroke (adjusted hazard ratio Q4:Q1 1.55, 95% CI 1.13-2.14) and cardiovascular death or heart failure (1.91, 1.20-3.03). In further multivariable assessment, increased activity levels of sPLA(2) were associated with the risk of cardiovascular death, myocardial infarction, or stroke (adjusted hazard ratio 1.47, 95% CI 1.06-2.04), independent of lipoprotein-associated phospholipase A(2) mass and C-reactive protein, and modestly improved the area under the curve (AUC) beyond established clinical risk factors (AUC 0.668-0.675, P = 0.01). sPLA(2), N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac troponin T all were independently associated with cardiovascular death or heart failure, and each improved risk discrimination (P = 0.02, P < 0.001, P < 0.001, respectively). CONCLUSIONS:sPLA(2) activity provides independent prognostic information beyond established risk markers in patients with stable CAD. These data are encouraging for studies designed to evaluate the role of sPLA(2) as a therapeutic target.
Authors: Meredith A Bostrom; Boris B Boyanovsky; Craig T Jordan; Marilyn P Wadsworth; Douglas J Taatjes; Frederick C de Beer; Nancy R Webb Journal: Arterioscler Thromb Vasc Biol Date: 2007-01-04 Impact factor: 8.311
Authors: K Kugiyama; Y Ota; K Takazoe; Y Moriyama; H Kawano; Y Miyao; T Sakamoto; H Soejima; H Ogawa; H Doi; S Sugiyama; H Yasue Journal: Circulation Date: 1999-09-21 Impact factor: 29.690
Authors: Ziad Mallat; Ph Gabriel Steg; Joëlle Benessiano; Marie-Laure Tanguy; Keith A Fox; Jean-Philippe Collet; Omar H Dabbous; Patrick Henry; Kathryn F Carruthers; Anne Dauphin; Carla Sibella Arguelles; Joëlle Masliah; Bénédicte Hugel; Gilles Montalescot; Jean-Marie Freyssinet; Bernard Asselain; Alain Tedgui Journal: J Am Coll Cardiol Date: 2005-10-04 Impact factor: 24.094
Authors: B Ivandic; L W Castellani; X P Wang; J H Qiao; M Mehrabian; M Navab; A M Fogelman; D S Grass; M E Swanson; M C de Beer; F de Beer; A J Lusis Journal: Arterioscler Thromb Vasc Biol Date: 1999-05 Impact factor: 8.311
Authors: Eugene Braunwald; Michael J Domanski; Sarah E Fowler; Nancy L Geller; Bernard J Gersh; Judith Hsia; Marc A Pfeffer; Madeline M Rice; Yves D Rosenberg; Jean L Rouleau Journal: N Engl J Med Date: 2004-11-07 Impact factor: 91.245
Authors: S Matthijs Boekholdt; Tymen T Keller; Nicholas J Wareham; Robert Luben; Sheila A Bingham; Nicholas E Day; Manjinder S Sandhu; J Wouter Jukema; John J P Kastelein; C Erik Hack; Kay-Tee Khaw Journal: Arterioscler Thromb Vasc Biol Date: 2005-02-03 Impact factor: 8.311
Authors: Michael V Holmes; Holly J Exeter; Lasse Folkersen; Christopher P Nelson; Montse Guardiola; Jackie A Cooper; Reecha Sofat; S Matthijs Boekholdt; Kay-Tee Khaw; Ka-Wah Li; Andrew J P Smith; Ferdinand Van't Hooft; Per Eriksson; Anders Franco-Cereceda; Folkert W Asselbergs; Jolanda M A Boer; N Charlotte Onland-Moret; Marten Hofker; Jeanette Erdmann; Mika Kivimaki; Meena Kumari; Alex P Reiner; Brendan J Keating; Steve E Humphries; Aroon D Hingorani; Ziad Mallat; Nilesh J Samani; Philippa J Talmud Journal: Circ Cardiovasc Genet Date: 2014-02-21
Authors: Michael V Holmes; Tabassome Simon; Holly J Exeter; Lasse Folkersen; Folkert W Asselbergs; Montse Guardiola; Jackie A Cooper; Jutta Palmen; Jaroslav A Hubacek; Kathryn F Carruthers; Benjamin D Horne; Kimberly D Brunisholz; Jessica L Mega; Erik P A van Iperen; Mingyao Li; Maarten Leusink; Stella Trompet; Jeffrey J W Verschuren; G Kees Hovingh; Abbas Dehghan; Christopher P Nelson; Salma Kotti; Nicolas Danchin; Markus Scholz; Christiane L Haase; Dietrich Rothenbacher; Daniel I Swerdlow; Karoline B Kuchenbaecker; Eleonora Staines-Urias; Anuj Goel; Ferdinand van 't Hooft; Karl Gertow; Ulf de Faire; Andrie G Panayiotou; Elena Tremoli; Damiano Baldassarre; Fabrizio Veglia; Lesca M Holdt; Frank Beutner; Ron T Gansevoort; Gerjan J Navis; Irene Mateo Leach; Lutz P Breitling; Hermann Brenner; Joachim Thiery; Dhayana Dallmeier; Anders Franco-Cereceda; Jolanda M A Boer; Jeffrey W Stephens; Marten H Hofker; Alain Tedgui; Albert Hofman; André G Uitterlinden; Vera Adamkova; Jan Pitha; N Charlotte Onland-Moret; Maarten J Cramer; Hendrik M Nathoe; Wilko Spiering; Olaf H Klungel; Meena Kumari; Peter H Whincup; David A Morrow; Peter S Braund; Alistair S Hall; Anders G Olsson; Pieter A Doevendans; Mieke D Trip; Martin D Tobin; Anders Hamsten; Hugh Watkins; Wolfgang Koenig; Andrew N Nicolaides; Daniel Teupser; Ian N M Day; John F Carlquist; Tom R Gaunt; Ian Ford; Naveed Sattar; Sotirios Tsimikas; Gregory G Schwartz; Debbie A Lawlor; Richard W Morris; Manjinder S Sandhu; Rudolf Poledne; Anke H Maitland-van der Zee; Kay-Tee Khaw; Brendan J Keating; Pim van der Harst; Jackie F Price; Shamir R Mehta; Salim Yusuf; Jaqueline C M Witteman; Oscar H Franco; J Wouter Jukema; Peter de Knijff; Anne Tybjaerg-Hansen; Daniel J Rader; Martin Farrall; Nilesh J Samani; Mika Kivimaki; Keith A A Fox; Steve E Humphries; Jeffrey L Anderson; S Matthijs Boekholdt; Tom M Palmer; Per Eriksson; Guillaume Paré; Aroon D Hingorani; Marc S Sabatine; Ziad Mallat; Juan P Casas; Philippa J Talmud Journal: J Am Coll Cardiol Date: 2013-07-31 Impact factor: 24.094